No Data
yifeng pharmacy chain (603939.SH): Controlling shareholder Houxin Venture Capital and its concerted parties reduced their holdings of "Yifeng Convertible Bonds" by a total of 2.205 million units.
On September 27, Gelonhui announced that from September 18, 2024 to September 26, 2024, Houxin Venture Capital and its concerted action persons reduced their holdings of 'Yifeng Convertible Bonds' by a total of 2,205,000 shares through the Shanghai Stock Exchange trading system, accounting for 12.27% of the total issuance. After this reduction, the company's controlling shareholders collectively hold 4,054,790 'Yifeng Convertible Bonds', accounting for 22.56% of the total convertible bonds issued by the company.
Express News | JPMorgan has given an initial overweight rating to the yifeng pharmacy chain.
Pharmaceutical commerce sector rebounds with volatility, LBX pharmacy chain hits the limit.
On September 19, Lbx Pharmacy Chain Joint Stock surged, followed by Yifeng Pharmacy Chain, Yunnan Jianzhijia Health-chain, Yixintang Pharmaceutical, and Shuyu Pingmin. Guosheng Securities' research report pointed out that the concentration of the pharmacy industry has increased and the trend of prescription drugs flowing out has not changed. With the aging population, leading pharmacy chains are expected to have stable and robust development. Looking ahead to 2024, the integration of outpatient clinics is expected to contribute significant growth, driving further increases in customer traffic and gross profit for pharmacies.
Yifeng Pharmacy Chain Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Express News | The pharmaceutical commerce sector continues to decline, and Yifeng pharmacy chain is approaching the limit down.
Pharmaceutical commerce stocks in A-shares fell, with Lbx Pharmacy Chain Joint Stock dropping more than 9%.
On September 2nd, Gelonghui reported that lbx pharmacy chain joint stock fell by more than 9%, yifeng pharmacy chain fell by more than 8%, dashenlin pharmaceutical group, yixintang pharmaceutical, yunnan jianzhijia health-chain, guangxi liuyao group, china national accord medicines corporation and others were among the top decliners.
No Data
No Data